Retraction: Receptor tyrosine kinases in carcinogenesis (Review) (Oncology Letters (2016) 12 (3679-3682) DOI: 10.3892/ol.2016.5200);Receptor tyrosine kinases in carcinogenesis (Review)

Oncology Letters

Volumn 12, Issue 5, 2016, Pages 3679-3682

  Zhang, Xiao Ying ^a   Zhang, Pei Ying ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Cancer; Receptor tyrosine kinase like orphan receptors; Receptor tyrosine kinases

Indexed keywords

CASEIN KINASE I; CETUXIMAB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN KINASE B; PROTEIN ROR1; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CELL INTERACTION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 84990060837     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2020.12062     Document Type: Erratum

References (47)

1. Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, Jeddi-Tehrani M, Akhondi MM, Bayat AA, Ghods R, Mahmoudi AR, Hadavi R, Österborg A, et al: Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 26: 1348-1355, 2012.
2. Shabani M, Naseri J and Shokri F: Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets 19: 941-955, 2015.
3. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A and Rader C: Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 14: 396-404, 2008.
4. Barna G, Mihalik R, Timár B, Tömböl J, Csende Z, Sebestyén A, Bödör C, Csernus B, Reiniger L, Peták I, et al: ROR1 expression is not a unique marker of CLL. Hematol Oncol 29: 17-21, 2011.
5. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R and Kipps TJ: The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 181: 1903-1910, 2012.
6. Wurz GT, Kao CJ and DeGregorio MW: Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 8: 4-31, 2016.
7. Uhrmacher S, Schmidt C, Erdfelder F, Poll-Wolbeck SJ, Gehrke I, Hallek M and Kreuzer KA: Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk Res 35: 1360-1366, 2011.
8. Ida L, Yamaguchi T, Yanagisawa K, Kajino T, Shimada Y, Suzuki M and Takahashi T: Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma. Cancer Sci 107: 155-161, 2016.
9. Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, Tang X, Xu N, Zhang D, Xiong L, Mao Y, Li F and Zhu J: ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 4: 5811 2014.
10. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, et al: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647, 2001.
11. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, et al: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194: 1625-1638, 2001.
12. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, Akhondi M, Lagercrantz S, Larsson C, Osterborg A, et al: Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 123: 1190-1195, 2008.
13. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, Khoshnoodi J, Roohi A, Jeddi-Tehrani M, Mellstedt H, et al: Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms’ tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 49: 1360-1367, 2008.
14. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, Toughe GR, Kordmahin M, Khoshnoodi J, Roohi A, et al: Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 28: 318-326, 2007.
15. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW and Kipps TJ: ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 7: e31127, 2012.
16. Rabbani H, Ostadkarampour M, Danesh Manesh AH, Basiri A, Jeddi-Tehrani M and Forouzesh F: Expression of ROR1 in patients with renal cancer - a potential diagnostic marker. Iran Biomed J 14: 77-82, 2010.
17. O’Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, et al: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3: 1378-1393, 2013.
18. Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M, Rabbani H and Mellstedt H: Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS One 8: e61167, 2013.
19. Shabani M, Asgarian Omran H, Farsangi MH, Vossough P, Sharifian RA, Toughe GR, Razavi SM, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H, et al: Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. Avicenna J Med Biotechnol 3: 119-125, 2011.
20. Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grandér D, Lehmann S, Norin S, Shokri F, Rabbani H, et al: Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma 54: 843-850, 2013.
21. Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin A, Mansouri L, Palma M, Lundin J, Österborg A and Mellstedt H: The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One 8: e78339, 2013.
22. Borcherding N, Kusner D, Liu GH and Zhang W: ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5: 496-502, 2014.
23. Li P, Harris D, Liu Z, Liu J, Keating M and Estrov Z: Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 5: e11859, 2010.
24. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF II, Rassenti LZ, Cantwell MJ, Prussak CE, et al: Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 105: 3047-3052, 2008.
25. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ and Tyner JW: Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 22: 656-667, 2012.
26. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H, et al: NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21: 348-361, 2012.
27. Cui B, Zhang S, Chen L, Yu J, Widhopf GF II, Fecteau JF, Rassenti LZ and Kipps TJ: Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 73: 3649-3660, 2013.
28. Graziano C: HER-2 breast assay, linked to Herceptin, wins FDA’s okay. CAP Today 12: 1, 14-16, 1998.
29. Herbst RS, Fukuoka M and Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-965, 2004.
30. Dowell J, Minna JD and Kirkpatrick P: Erlotinib hydrochloride. Nat Rev Drug Discov 4: 13-14, 2005.
31. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263, 2002.
32. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, et al: Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17: 1351-1361, 2011.
33. Yuan HH, Han Y, Bian WX, Liu L and Bai YX: The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines. Pathology 44: 547-551, 2012.
34. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, et al: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30: 1989-1995, 2012.
35. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A and Rader C: Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 6: e21018, 2011.
36. Widhopf GF II, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM and Kipps TJ: ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice. Proc Natl Acad Sci USA 111: 793-798, 2014.
37. Cui B, Widhopf GF II, Prussak CE, Wu CCN, Sadarangani A, Zhang S, Lao F, Jamieson CHM, Carson DA and Kipps TJ: Cirmtuzumab vedotin (UC-961ADC3), an anti-ROR1-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for ROR1-positive leukemia and solid tumors. Presented at 55th ASH Annual Meeting. (abstract 1637), 2013. https://ash.confex.com/ash/2013/webprogram/Paper65533.html.
38. Baskar S, Wiestner A, Wilson WH, Pastan I and Rader C: Targeting malignant B cells with an immunotoxin against ROR1. MAbs 4: 349-361, 2012.
39. Gilbert JA: Lenalidomide as first-line therapy for elderly CLL patients. Lancet Oncol 14: e345, 2013.
40. Hojjat-Farsangi M, Daneshmanesh AH, Osterborg A, Shokri F and Mellstedt H: Patients with chronic lymphocyte leukemia (CLL) have naturally occurring antibodies against the receptor tyrosine kinase (ROR1). Blood (ASH Annual Meeting abstracts) 118: 1771, 2011.
41. Yu J, Cui B, Widhopf GF II, Chen L, Rassenti L, Wang Z, Ma S, Hayashi T, Carson DA and Kipps TJ: Preclinical development of ROR1 peptide based vaccine with activity against chroniclymphocytic leukemia in ROR1 transgenic mice. Blood (ASH Annual Meeting abstracts) 122: 4174, 2013.
42. Milani A, Sangiolo D, Montemurro F, Aglietta M and Valabrega G: Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 24: 1740-1748, 2013.
43. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C and Riddell SR: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19: 3153-3164, 2013.
44. Robertson SC, Tynan J and Donoghue DJ: RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 16: 368, 2000.
45. Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8: 161-173, 2001.
46. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D and Kay NE: The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 117: 1928-1937, 2011.
47. Paesler J, Gehrke I, Gandhirajan RK, Filipovich A, Hertweck M, Erdfelder F, Uhrmacher S, Poll-Wolbeck SJ, Hallek M and Kreuzer KA: The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res 16: 3390-3398, 2010.